Immunomic Therapeutics inks license deal with Ichor

By The Science Advisory Board staff writers

June 16, 2020 -- Immunomic Therapeutics (ITI) has signed a licensing agreement with Ichor Medical Systems to support the development of its ITI-1001 investigational plasmid DNA vaccine therapy.

ITI will use Ichor's TriGrid electroporation delivery technology to increase the cellular uptake of ITI-1001 when administered to patients with newly diagnosed glioblastoma multiforme (GBM). ITI-1001 is designed to target the pp65, ie-1, and gB viral antigens of cytomegalovirus (CMV), which are expressed in GBM, but not in normal brain cells, according to the company.

The first in-human phase I study for ITI-1001 is expected to begin in 2021.

New drug target identified for common brain cancer
Research led by the Cleveland Clinic has identified a potential new therapy in the treatment of glioblastoma. An article published in Cancer Discovery...

Copyright © 2020

Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter